WhiteLab Genomics is a Paris-headquartered TechBio company, founded in 2019 by David Del Bourgo and Julien Cottineau, whose AI platform runs in-silico simulations for the design of gene, cell, RNA and DNA therapies, from target discovery to vector and payload design and genotoxicity assessment. Rather than trial-and-error wet-lab testing, its predictive models rank candidate therapy designs before experiments begin, serving biotech and pharma customers in Europe and the US with additional sites in North America. A Y Combinator Winter 2022 graduate, it went on to raise a $10M Series A co-led by Debiopharm Innovation Fund alongside Omnes Capital in September 2022.
1
Round
1
Industry
5
Tags
Oct 5, 2026
Latest raise
Funding activity · 1 round
Oct 5, 2026
$26M
Series B
Led by AVP (Atlantic Vantage Point)
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
